Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 showing deepening of confirmed responses in checkpoint inhibitor-refractory solid tumors PLN-101095 spotlighted as novel IO